Eurofins Genomics

Eurofins Genomics, founded in 1999, is a mission-critical service provider in the genomics sector, enabling global research and development through its 'read and write DNA' business model. Its achievements are built on a proprietary high-throughput synthesis platform, offering industry-leading speed for probes and primers, and a comprehensive sequencing portfolio spanning gold-standard Sanger to modern Nanopore technologies. The company's strategy leverages its position within the Eurofins Scientific network to deliver customer-centric, high-quality services with efficient logistics, serving a diverse, international client base across multiple high-growth life science sectors.

Proprietary high-throughput, automated DNA synthesis platform enabling rapid production of oligonucleotides, complemented by optimized Sanger and integrated Nanopore sequencing technologies and a suite of bioinformatic design and collaboration tools.

Eurofins Genomics competes in a fragmented market against giants like IDT (Danaher) in synthesis and Azenta in sequencing, as well as innovators like Twist Bioscience. Its advantages lie in its unique combination of speed, a comprehensive 'read & write' portfolio, regulatory-grade offerings, and the backing of the global Eurofins Scientific network.